In vitro and in vivo antipseudomonal activity, acute toxicity, and mode of action of a newly synthesized fluoroquinolonyl ampicillin derivative

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 3, 2003, Pages 158-165

  Lin, Wen Po ^a   Ji, Dar Der ^a   Shiau, Chia Yang ^a   Yang, Tse Chun ^a   Yang, Yung Wen ^a   Tsou, Tai Li ^a   Tang, Shang Tao ^a   Chen, Chi Hsing ^a   Liu, Yu Tien ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN DERIVATIVE; DOUBLE STRANDED DNA; GENTAMICIN; N (6 FLUOROQUINOLONYL)AMPICILLIN; N (6,7 DIFLUOROQUINOLONYL)AMPICILLIN; NORFLOXACIN; PENICILLINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CROSS LINKING; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; EXPERIMENTAL MOUSE; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; MOUSE; NEUTROPENIA; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; PROTOPLAST; PSEUDOMONAS AERUGINOSA; SURVIVAL RATE;

EID: 0141956246     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00112-4     Document Type: Article

References (26)

1. Mokaddas EM, Sanyal SC. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam. J Chemother 1999;11:93-6.
2. Sheretz RJ, Sarubbi FA. A three-year study of nosocomial infections associated with Pseudomonas aeruginosa. J Clin Microbiol 1993;18:160-4.
3. Ojeniyi B, Petersen US, Hoiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 1993;101:168-75.
4. Sader HS, Pignatari AC, Leme IL, Burattin MN, Tancresi R, Hollis RJ, et al. Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. Diagn Microbiol Infect Dis 1993;17:13-8.
5. Sanders CC, Samers WE, Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, β-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984;26: 797-801.
6. Kresken J, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction to norfloxacin and ofloxacin. Antimicrob Agents Chemother 1988;32:1285-8.
7. Leaves NI, Dimopoulou I, Hayes I, Kerridge S, Falla T, Secka O, et al. Epidemiological studies of large resistance plasmids in Haemophilus. J Antimicrob Chemother 2000;45:599-604.
8. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
9. Jalal S, Wretlind G, Gotoh N, Wretlind B. Rapid identification of mutations in a multidrug efflux pump in Pseudomona aeruginosa. APMIS 1999;107:1109-16.
10. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999;2:11-8.
11. Pong A, Thomson KS, Chartrand SA, Sanders CC. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 1999:44:621-27.
12. Mouneimne H, Robert J, Jarlier V, Cambau E. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:62-6.
13. Albrecht HA, Beskid G, Chan KK, Christenson JG, Cleeland R, Deitcher KH, et al. Cephalosporin 3′-quinolone esters with a dual mode of action. J Med Chem 1990;33:77-86.
14. Albrecht HA, Beskid G, Christrenson JG, Durkin JW, Fallat V, Georgopapadakou NH, et al. Dual-action cephalosporins: cephalosporin 3′-quaternary ammonium quinolones. J Med Chem 1991;34:669-75.
15. Albrecht HA, Beskid G, Christrenson JG, Georgopapadakou NH, Keith DD, Konzelmann FM, et al. Dual-action cephalosporins: cephalosporin 3′-quinolone carbamates. J Med Chem 1991;34: 2857-64.
16. Demuth TP, White RE, Tietjen RA, Storrin RJ, Skuster JR, Andersen JA, et al. Synthesis and antibacterials activity of new C-10 quinolonyl-cephem esters. J Antibiotics 1991;44:200-9.
17. Chen CH, Tsou TL, Chiang HY, Lee SH, Lee F, Wang TM, et al. Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative N-(6,7-difluoroquinolonyl)-ampicillin. J Antimicrob Chemother 1997;39:325-30.
18. Tsou TL, Tang ST, Wu JR, Hung YW, Liu YT. Synthesis and antipseudomonal activity of fluoroquinolonyl-penicillin derivatives. Eur J Med Chem 1999;34:255-9.
19. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med 1984; 103:878-85.
20. Reed LJ, Muench H. A simple method of estimating fifty per cent end points. Am J Hyg 1938;27:493-7.
21. Liu YT, Yeh SJ, Liao CL, Chou CF, Shou L. Mechanism of action of chounghwamycin A. Proc Natl Sci Coun R O C 1989;13(part B):262-6.
22. Bonfiglio G, Laksai Y, Franchino L, Amicosant G, Nicoletti G. Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. J Antimicrob Chemother 1998;42:697-702.
23. Vuopio-Varkila J. Experimental Escherichia coli peritonitis in immunosupressed mice: the role of specific and non-specific immunity. J Med Microbiol 1988;25:33-9.
24. Pedersen LB, Angert ER, Setlow P. Septal localization of penicillin-binding protein 1 in Bacillus subtilis. J Bacteriol 1999;181: 3201-11.
25. Levin PA, Losick R. Characterization of a cell division gene from Bacillus subtilis that is required for vegetative and sporulation septum formation. J Bacteriol 1994;176:1451-9.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.